Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient

### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University

CAR-T Therapy

On November 7, 2023, China’s first CAR-T product for treating adult leukemia, Yuan Ruida (Inaticabtagene Autoleucel Injection), was officially approved for market release. This marks a significant breakthrough in the field of leukemia cellular immunotherapy in China. Recently, The First Affiliated Hospital of Chongqing Medical University successfully treated a young patient with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL), demonstrating the remarkable efficacy of this innovative therapy.

**Successful Case**

The patient, a 20-year-old female, was diagnosed with Ph+ B-ALL in early 2021. Despite undergoing tyrosine kinase inhibitors (TKI) combined with chemotherapy and hematopoietic stem cell transplantation (HSCT), her disease relapsed multiple times. Finally, she tried CAR-T therapy. On February 23, 2024, the patient received a transfusion of Inaticabtagene Autoleucel Injection. Just one month after the transfusion, she achieved complete remission (CR) and minimal residual disease (MRD) negativity. Currently, the patient is recovering well and is about to return to school.

**Professional Care from the Medical Team**

Throughout the treatment, the expert team at The First Affiliated Hospital of Chongqing Medical University demonstrated exceptional medical skills and meticulous care. Professor Li noted that after multiple treatment failures, the patient chose the innovative therapy of Inaticabtagene Autoleucel Injection, which ultimately yielded gratifying results. During the CAR-T transfusion, the medical team closely monitored the patient’s condition, ensuring the safety and effectiveness of the treatment. The patient’s positive attitude and family support also laid the foundation for successful treatment.

**Support from Commercial Insurance**

This treatment not only relied on advanced medical technology but also benefited from the support of the patient’s family’s commercial insurance. During the treatment, the patient’s family actively applied for commercial insurance claims and successfully obtained full compensation, significantly reducing the financial burden. The support from commercial insurance increased the accessibility of the treatment, providing solid backing for the patient’s recovery.

**Future Prospects**

The approval of Inaticabtagene Autoleucel Injection has brought new hope to B-ALL patients, especially young ones. The excellent efficacy and safety of CAR-T therapy will significantly improve their quality of life. With more successful cases emerging, CAR-T therapy is expected to become the new standard for B-ALL treatment.

The successful case at The First Affiliated Hospital of Chongqing Medical University not only showcases the immense potential of Inaticabtagene Autoleucel Injection in treating leukemia but also provides valuable experience and reference for future clinical applications. The patient’s recovery journey is inspiring, symbolizing not only physical recovery but also a rebirth of the spirit.

**Conclusion**

The successful application of CAR-T therapy has shown leukemia patients a light of recovery. The professional team at The First Affiliated Hospital of Chongqing Medical University will continue to promote this innovative therapy, bringing hope and new life to more patients. With the advancement of medical technology and the support of commercial insurance, the future of patients will be even brighter.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com

#CARTherapy #LeukemiaTreatment #InnovativeMedicine #ChongqingMedicalUniversity #MedicalBreakthrough #NewLife #CommercialInsurance #PatientRecovery #CancerTreatment #MedicalTechnology #PatientStory #MedicalAdvancement #HopeAndHealing #ChineseHealthcare #CARTTreatment #PhALL #HealthyFuture

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 *Haematologica Spotlight* 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

    is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and extramedullary sites. While the prognosis for childhood ALL is relatively favorable, with a 5-year overall survival rate of 80-90%, adult ALL poses greater challenges. Approximately 20-30% of adult acute leukemias are ALL, with about two-thirds being Philadelphia chromosome-negative (Ph-negative) ALL. Conventional adult ALL treatments have shown high remission rates but also high relapse rates and poor long-term survival.

Haematologica

Inspired by the success of pediatric ALL treatments, especially in adolescent and young adult patients, the Hematology Center at the

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

    embarked on a groundbreaking journey. Their pioneering research, recently published in *Haematologica*, presents the results of the largest prospective cohort study in China investigating the efficacy of a pediatric-inspired regimen in adult Ph-negative ALL patients.

 

The study, led by Dr. Wang Jianxiang and his team,

    evaluated the IH-2014 regimen’s effectiveness in 415 newly diagnosed adult Ph-negative ALL patients treated between April 2014 and December 2021, with a median age of 27 years (range 14-65 years) and a median follow-up of 40.8 months. The overall 5-year overall survival (OS) and disease-free survival (DFS) rates were 53.8% and 51.1%, respectively, with a chemotherapy-related mortality rate of 3.6%.

 

Patients achieving complete remission (CR)

    after induction therapy with available bone marrow minimal residual disease (MRD) data were categorized based on diagnostic risk: standard-risk (SR) MRD-negative (<0.01%) in 73 patients (18.8%), SR MRD-positive (≥0.01%) in 69 patients (17.7%), high-risk (HR) MRD-negative in 120 patients (30.8%), and HR MRD-positive in 127 patients (32.6%). The 5-year OS rates for these groups were 82.6%, 58.7%, 58.3%, and 36.1%, respectively (P＜0.001), with corresponding cumulative relapse rates of 24.2%, 41.1%, 36.3%, and 50.1% (P＜0.001). Multivariate analysis identified age ≥40 years and MRD positivity after induction as independent adverse prognostic factors for OS and DFS.

 

In conclusion, the IH-2014 regimen demonstrates significant efficacy and good tolerability in adult Ph-negative ALL patients, with younger patients (<40 years) benefiting more prominently. Induction treatment response combined with MRD levels serves as a valuable prognostic indicator for long-term survival and relapse, guiding allogeneic hematopoietic stem cell transplantation decisions in patients achieving first complete remission (CR1).

 

This study marks a pivotal milestone in advancing adult ALL treatment strategies, showcasing China’s remarkable progress in the field of hematology. Stay tuned for more groundbreaking research from our team!

 

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

 

🌟 #Haematologica #LeukemiaTreatment #PediatricInspiration #ALL #AcuteLymphoblasticLeukemia #LymphoblasticLeukemia #Leukemia